Background
Results
All patients | PV | ET | PMF | Post-PV-MF | Post-ET-MF | MPN-U |
p value | |
---|---|---|---|---|---|---|---|---|
Patients; n (% of total) | 454 | 142 (31.3) | 140 (30.8) | 113 (24.9) | 22 (4.8) | 19 (4.2) | 18 (4.0) | |
Male sex; n (%) | 232 (51.1)
n = 454 | 65 (45.8)
n = 142 | 57 (40.7)
n = 140 | 76 (67.3)
n =113 | 11 (50)
n = 22 | 12 (63.2)
n = 19 | 11 (61.1)
n = 18 | 0.0007#
|
Age at diagnosis; median, mean (SD) | 60 57.7 (15.2)
n = 442 | 60 59.2 (13.9)
n = 140 | 54 52.9 (16.5)
n = 137 | 61.5 60.6 (13.4)
n = 108 | 63 58.4 (12.6)
n = 21 | 68 63.9 (17.8)
n = 18 | 57.5 57 (18.4)
n = 18 | 0.0008* |
Hematocrita; median, mean (SD) | 42.5 41.9 (10.9)
n = 441 | 50 49.5 (10.6)
n = 139 | 41.6 40.4 (7.9)
n = 137 | 34.6 35.4 (9.6)
n = 108 | 46 42.7 (10)
n = 21 | 34.7 34.7 (7.9)
n = 18 | 42.1 38.9 (7.2)
n = 18 | <0.0001* |
Plateletsa; median, mean (SD) | 516 575.2 (383.7)
n = 441 | 487 522.2 (269.3)
n = 137 | 704 789.1 (410.1)
n = 139 | 376 429.4 (374.4)
n = 109 | 395.5 446.2 (325.8)
n = 20 | 279.5 359.3 (271.1)
n = 18 | 502.5 568.3 (425.3)
n = 18 | <0.0001* |
LDHa; median, mean (SD) | 307 415.2 (332.5)
n = 409 | 282 308.3 (121.2)
n = 128 | 252 314.2 (209.9)
n = 130 | 462 565.8 (326.8)
n = 101 | 593.5 717.9 (599.5)
n = 18 | 670 913.7 (835.8)
n = 15 | 310 336.8 (162)
n = 17 | <0.0001* |
Jak2V617F-positive; n (%) | 289 (75.5)
n = 383 | 108 (91.5)
n = 118 | 71 (61.7)
n = 115 | 68 (68)
n = 100 | 18 (100)
n = 18 | 9 (60)
n = 15 | 15 (88.2)
n = 17 | <0.0001#
|
Spleen in cm by ultrasounda; median, mean (SD) | 14.5 15.6 (5.4)
n = 243 | 13.8 14.6 (3.7)
n = 75 | 12.5 13.2 (3.4)
n = 61 | 16.2 16.5 (4.2)
n = 69 | 23.1 23.9 (12.7)
n = 14 | 17.4 18.3 (5.3)
n = 14 | 15.5 16.1 (3.9)
n = 10 | <0.0001* |
All Pts | PV | ET | PMF | Post-PV-MF | Post-ET-MF | MPN-U |
p value#
| |
---|---|---|---|---|---|---|---|---|
Thrombosis/thromboembolisma; n (%) | 147 (33.6)
n = 438 | 54 (38.9)
n = 139 | 33 (25)
n = 132 | 34 (31.2)
n = 109 | 13 (61.9)
n = 21 | 8 (42.1)
n = 19 | 5 (27.8)
n = 18 |
0.0120
|
DVT; n (%) | 46 (31.5)
n = 146 | 15 (27.8)
n = 54 | 10 (30.3)
n = 33 | 11 (33.3)
n = 33 | 4 (30.8)
n = 13 | 3 (37.5)
n = 8 | 3 (60)
n = 5 | 0.7781 |
ACS; n (%) | 41 (27.7)
n = 148 | 15 (27.8)
n = 54 | 12 (35.3)
n = 34 | 7 (20.6)
n = 34 | 4 (30.8)
n = 13 | 2 (25)
n = 8 | 1 (20)
n = 5 | 0.8439 |
Stroke; n (%) | 28 (19.3)
n = 145 | 13 (24.5)
n = 53 | 7 (21.2)
n = 33 | 7 (21.2)
n = 33 | 0 (0)
n = 13 | 0 (0)
n = 8 | 1 (20)
n = 5 | 0.2714 |
SVT; n (%) | 22 (15.2)
n = 145 | 3 (5.7)
n = 53 | 6 (18.2)
n = 33 | 6 (18.2)
n = 33 | 4 (30.8)
n = 13 | 0 (0)
n = 8 | 3 (60)
n = 5 |
0.0083
|
Bleedinga, n (%) | 36 (8.2)
n = 437 | 13 (9.4)
n = 139 | 5 (3.8)
n = 133 | 10 (9.3)
n = 108 | 4 (19.1)
n = 21 | 1 (5.3)
n = 19 | 3 (17.7)
n = 17 | 0.0586 |
Upper GI-Tract-Bleeding; n (%) | 20 (55.6)
n = 36 | 7 (53.9)
n = 13 | 3 (69)
n = 5 | 6 (60)
n = 10 | 3 (75)
n = 4 | 0 (0)
n = 1 | 1 (33.3)
n = 3 | 0.8748 |
Postinterventional; n (%) | 4 (11.1)
n = 36 | 3 (23.1)
n = 13 | 0 (0)
n = 5 | 0 (0)
n = 10 | 0 (0)
n = 4 | 1 (100)
n = 1 | 0 (0)
n = 3 | 0.0958 |
CNS; n (%) | 3 (8.3)
n = 36 | 0 (0)
n = 13 | 0 (0)
n = 5 | 3 (30)
n = 10 | 0 (0)
n = 4 | 0 (0)
n = 1 | 0 (0)
n = 3 | 0.1725 |
All patients | PV | ET | PMF | Post-PV-MF | Post-ET-MF | MPN-U |
p value#
| |
---|---|---|---|---|---|---|---|---|
Antiplatelet drugs | ||||||||
ASSa; n (%) | 248 (57.4)
n = 432 | 92 (67.2)
n = 137 | 83 (61.5)
n = 135 | 45 (42.9)
n = 105 | 11 (61.1)
n = 18 | 10 (52.6)
n = 19 | 7 (38.9)
n = 18 |
0.0026
|
P2Y12 antagonista; n (%) | 27 (6.4)
n = 425 | 9 (6.7)
n = 134 | 13 (9.7)
n = 134 | 4 (3.9)
n = 104 | 0 (0)
n = 17 | 0 (0)
n = 18 | 1 (5.6)
n = 18 | 0.4064 |
Anticoagulants | ||||||||
VKA; n (%) | 43 (9.8)
n = 437 | 14 (10.1)
n = 138 | 13 (9.5)
n = 137 | 6 (5.6)
n = 107 | 4 (21.1)
n = 19 | 3 (16.7)
n = 18 | 3 (16.7)
n = 18 | 0.1511 |
Rivaroxaban; n (%) | 8 (1.8)
n = 437 | 3 (2.2)
n = 138 | 1 (0.7)
n = 137 | 4 (3.7)
n = 107 | 0 (0)
n = 19 | 0 (0)
n = 18 | 0 (0)
n = 18 | 0.6151 |
Heparin; n (%) | 16 (3.8)
n = 417 | 4 (3.1)
n = 131 | 4 (3.1)
n = 131 | 5 (4.9)
n = 103 | 2 (11.1)
n = 18 | 1 (5.9)
n = 17 | 0 (0)
n = 17 | 0.4345 |
Anti-MPN therapyb
| ||||||||
Watch wait; n (%) | 226c
(51.7)
n = 437 | 79 (57.7)
n = 137 | 72 (52.9)
n = 136 | 49 (46.2)
n = 106 | 7 (33.3)
n = 21 | 6 (31.6)
n = 19 | 13 (72.2)
n = 18 |
0.0321
|
Hydroxyurea; n (%) | 215 (49.2)
n = 437 | 82 (59.9)
n = 137 | 67 (49.3)
n = 136 | 38 (35.9)
n = 106 | 10 (47.6)
n = 21 | 9 (47.4)
n = 19 | 9 (50)
n = 18 |
0.0151
|
Anagrelide; n (%) | 66 (15.1)
n = 437 | 15 (11.0)
n = 137 | 32 (23.5)
n = 136 | 11 (10.4)
n = 106 | 3 (14.3)
n = 21 | 4 (21.1)
n = 19 | 1 (5.6)
n = 18 |
0.0255
|
Ruxolitinib; n (%) | 87 (19.9)
n = 437 | 15 (11.0)
n = 137 | 5 (3.7)
n = 136 | 43 (40.6)
n = 106 | 11 (52.4)
n = 21 | 12 (63.2)
n = 19 | 1 (5.6)
n = 18 |
<0.0001
|
IMIDe; n (%) | 21 (4.8)
n = 437 | 2 (1.5)
n = 137 | 0 (0)
n = 136 | 15 (14.2)
n = 106 | 2 (9.5)
n = 21 | 1 (5.3)
n = 19 | 1 (5.6)
n = 18 |
<0.0001
|
IFNα; n (%) | 40 (9.2)
n = 437 | 12 (8.8)
n = 137 | 15 (11.0)
n = 136 | 9 (8.5)
n = 106 | 2 (9.5)
n = 21 | 1 (5.3)
n = 19 | 1 (5.6)
n = 18 | 0.9681 |
SCT; n (%) | 20 (4.6)
n = 439 | 3 (2.2)
n = 139 | 0 (0)
n = 134 | 12 (11.1)
n = 108 | 2 (9.5)
n = 21 | 2 (10.5)
n = 19 | 1 (5.6)
n = 18 |
<0.0001
|
Odds ratio (OR) | 95 % CI | |
---|---|---|
Diagnosis | ||
PV | 1.4309 | 0.9398–2.1786 |
ET |
0.5614
|
0.3554–0.8867
|
PMF | 0.8665 | 0.5445–1.3792 |
Post-PV-MF |
3.4319
|
1.3892–8.4783
|
Post-ET-MF | 1.4650 | 0.5762–3.7248 |
MPN-U | 0.7530 | 0.2632–2.1540 |
Jak2V617F-positive | 1.4785 | 0.8732–2.5034 |
High leukocytes (>25/nl) | 1.1500 | 0.6593–2.0059 |
High platelets (>1000/nl) | 0.7163 | 0.3738–1.3727 |
Splenomegaly (detected by palpation) |
1.7623
|
1.1480–2.7052
|
Odds ratio (OR) | 95 % CI | |
---|---|---|
Diagnosis | ||
PV | 1.2480 | 0.6123–2.5439 |
ET |
0.3440
|
0.1307–0.9053
|
PMF | 1.1892 | 0.5539–2.5531 |
Post-PV-MF | 2.8235 | 0.8964–8.8935 |
Post-ET-MF | 0.6079 | 0.0788–4.6904 |
MPN-U | 2.5130 | 0.6872–9.1897 |
Thrombotic/thromboembolic event in medical history |
2.7083
|
1.3578–5.4021
|
Splenomegaly (detected by palpation) |
2.2222
|
1.0095–4.8919
|
Low platelets (<100/nl) | 1.3120 | 0.5504–3.1275 |
High platelets (>1000/nl) | 1.1874 | 0.4401–3.2035 |
ASS | 1.1216 | 0.5539–2.2712 |
P2Y12 antagonist | 2.8292 | 0.9979–8.0213 |
Double platelet inhibition | 3.0500 | 0.9589–9.7016 |
Oral vitamin K antagonist | 1.9739 | 0.7695–5.0634 |
Rivaroxaban | 1.6092 | 0.1923–13.4665 |
Heparin |
5.6426
|
1.8360–17.3421
|